Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
- Conditions
- HIV Infections
- Registration Number
- NCT00025727
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV drugs without success.
- Detailed Description
Patients will receive 2 dosing regimens of GW433908/RTV or LPV/RTV, in combination with 2 active RTIs, after failing their first or second protease inhibitor-containing regimen. Patients are required to be on therapy at time of screening and must remain on this therapy until Day 1.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 330
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (32)
Phoenix Body Positive
๐บ๐ธPhoenix, Arizona, United States
Ocean View Internal Medicine
๐บ๐ธLong Beach, California, United States
Bisher Akil
๐บ๐ธLos Angeles, California, United States
Tower ID Med Associates
๐บ๐ธLos Angeles, California, United States
Orange Coast Med Group
๐บ๐ธNewport Beach, California, United States
Pacific Horizons Med Group
๐บ๐ธSan Francisco, California, United States
Denver Inf Disease Consultants
๐บ๐ธDenver, Colorado, United States
Physicans Home Service
๐บ๐ธWashington, District of Columbia, United States
IDC Research Initiative
๐บ๐ธAltamonte Springs, Florida, United States
Bach and Godofsky
๐บ๐ธBradenton, Florida, United States
Scroll for more (22 remaining)Phoenix Body Positive๐บ๐ธPhoenix, Arizona, United States